ScreenPoint Medical drummed up $5.0 million in a funding round led by the healthcare business at Siemens (NYSE:SI), saying it’s earmarked the proceeds for its Transpara mammography evaluation software.
Siemens Healthineers was joined by private investors in the €4.3 million round, Nijmegen, Holland-based ScreenPoint said. The Transpara software uses deep learning and image databases to aid in evaluating mammograms. The collaboration doesn’t stop at cash, as ScreenPoint said a strategic collaboration in precision medicine for breast imaging is in the works with the German conglomerate.
The company claims that Transpara performs as well as radiologists and cited study data showing that detection performance improved when radiologists used the technology. Transpara has CE Mark approval in the European Union for mammography and digital breast tomosynthesis, ScreenPoint said.
“Interpreting mammograms is one of the most challenging tasks in radiology and a shortage of skilled radiologists exists in many regions around the world. While breast cancer incidence continues to rise, innovative artificial intelligence solutions are needed to ensure that the high quality of screening programs can be maintained,” CEO Nico Karssemeijer said in prepared remarks. “We are very excited about the opportunity to partner with Siemens Healthineers in creating and delivering best-in-class services to customers to improve women’s health. The partnership enables accelerated market introduction of Transpara, which will remain a vendor neutral solution for breast screening”.
($1 = €0.858100)